Answers are grounded in this paper and cite their sources.
This injectable hydrogel reveals improved antibiofilm and anti-inflammation effects in diabetic wounds, suggesting enhanced healing.
Chronic diabetic wounds pose severe challenges in the clinic due to drug-resistant biofilm infections and an inflammatory microenvironment. Herein, an injectable hydrogel (NPs@gel) is developed and applied for antibiofilm and anti-inflammation, accelerating diabetic wound healing. First, an o-nitrobenzene (NB)-modified conjugated polyfluorene vinylene photosensitizer (PFV-NB) is designed and synthesized. Then, PFV-CA NPs are prepared, containing PFV-NB, chloramphenicol, and astaxanthin (AST), followed by the construction of NPs@gel. Notably, under light irradiation, PFV-NB can generate aldehyde groups that adhere to the biofilm through the Schiff base reaction, inhibiting the bacterial drug efflux pump, resensitizing the chloramphenicol, and damaging the biofilm. Meanwhile, PFV-NB can produce reactive oxygen species, further enabling photodynamic therapy and antibiofilm activity. Also, AST can alleviate inflammation after antibacterial treatment and regulate the diabetic wound microenvironment. Finally, NPs@gel can perfectly cover irregular wounds and realize programmed diabetic wound therapy. This work provides a promising synergistic strategy and material for the efficient treatment of chronic wounds.
No takes yet. Share an insight, caveat, or question.
Li et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: